José Prados *

Autor invitado por SIIC

Este trabajo apoya la hipótesis de la modulación en la expresión de CMH tras la aparición de resistencia a drogas en células tumorales

LA RESISTENCIA A DROGAS MODIFICA LAS CARACTERISTICAS INMUNOLOGICAS DE LOS RABDOMIOSARCOMAS

Los rabdomiosarcomas embrionarios desarrollan resistencia a la quimoterapia convencional debido a la expresión de P-glicoproteína/Mdr1. Dicha resistencia determina el pronóstico de la enfermedad y modifica las características inmunológicas de las células tumorales que aumentan significativamente su expresión de HLA de calse I. Este cambio puede ser de enorme importancia en la determinación de nuevas vías de tratamiento que mejoren su pronóstico.

*José Prados
describe para SIIC los aspectos relevantes de su trabajo
INDUCTION OF DRUG RESISTANCE IN EMBRYONAL RHABDOMYOSARCOMA TREATED WITH CONVENTIONAL CHEMOTHERAPY IS ASSOCIATED WITH HLA CLASS I INCREASE
Institución principal de la investigación
*Instituto de Biopatología y Medicina Regenerativa (IBIMER), Granada, España, Granada, España
Imprimir nota

Comprar este artículo
Otros artículos escogidos

Referencias bibliográficas
1. Raney RB: Soft-tissue sarcoma in childhood and adolescence. Curr Oncol Rep 2002; 4:291-298.2. Krishna R, Mayer LD. Multidrug resistance (MDR) in cancer. Mechanism, reversal using modulators and the role of MDR modulators in influencing the pharmacokinetics of anticancer. Eur J Pharm Sci 2000; 11:265-283.3. Komdeur R, Plaat BE, Van der Graf WT, Hoekstra HJ, Hollema H et al. Expression of multidrug resistance proteins, P-gp, MRP1 and LRP, in soft tissue sarcomas analysed according to their histological type and grade. Eur J Cancer. 2003; 39:909-916.4. Ambudkar SV, Kimchi-Sarfaty C, Sauna ZE, Gottesman MM. P-glycoprotein: from genomics to mechanism. Oncogene 2003, 22:7468-7685.5. Breier A, Barancik M, Sulova Z, Uhrik B. P-glycoprotein-implications of metabolism of neoplastic cells and cancer therapy. Curr Cancer Drug Targets 2005; 5:457-468.6. Melguizo C, Prados J, Marchal JA, Vélez C, Carrilo E et al. Expression of HLA Class I but not HLA Class II antigens is modulated by P-glycoprotein in resistant human rhabdomyosarcoma cells. Neoplasma 2003; 50:91-96.7. García Lora A, Algarra I, Garrido F. MHC class I antigens, immune surveillance, and tumor immune escape. J Cell Physiol 2003; 195:346-355.8. Ramnath N, Tan D, Li Q, Hylander BL, Bogner P et al. Is downregulation of MHC class I antigen expression in human non-small cell lung cancer associated with prolonged survival Cancer Immunol Immunother 2005; 27:1-9.9. Melguizo C, Prados J, Aneiros J, Fernández JE, Vélez C et al. Differentiation of a human rhabdomyosarcoma cell line after antineoplastic drug treatment. J Pathol 1995; 175:23-39.10. Leuschner I, Heuer T, Harms D. Induction of drug resistance in human rhabdomyosarcoma cell lines is associated with increased maturation: possible explanation for differentiation in recurrences. Pediatr Devel Pathol 2002; 5:276-282.11. Staibano S, Franco R, Mezza E, Lo Muzio L, Strianese D et al. Orbital rhabdomyosarcoma: relationship between DNA ploidy, p53, bcl-2, MDR-1 and Ki67 (MIB1) expression and clinical behavior. Anticancer Res 2004, 24:249-257.12. Leuschner I, Harms D, Mattke A, Koscielniak E, Treuner J. Rhabdomyosarcoma of the urinary bladder and vagina: a clinicophatologic study with emphasis of recurrent disease: a report of the Kiel Pediatric Tumo.13. García Lora A,. Algarra I, Collado A, Garrido F. Tumour immunology, vaccination and escape strategies. Eur J Immunogenet 2003; 30:177-183.14. Gallego S, Llort A, Parareda A, Sánchez de Toledo J. Expression of multidrug resistance-1 and multidrug resistance-associated protein genes in pediatric rhabdomyosarcoma. Oncol Rep 2004; 11:179-183.15. Ramnath N, Tan D, Li Q, Hylander BL, Bogner P et al. Is downregulation of MHC class I antigen expression in human non-small cell lung cancer associated with prolonged survival Cancer Immunol Immunother 2005; 27:1-9.